BioSpace News Archive

Drug Development

Merck’s Molnupiravir Sheds Efficacy Points Ahead of Key FDA Meeting

The latest data from Merck and Ridgeback Biotherapeutics’ MOVe-OUT trial on the use of molnupiravir to treat COVID-19 in adults has shown a lower efficacy than previously reported.

November 29, 2021
·
2 min read
·
Vanessa Doctor, RN
Drug Development

How Close Are We to Forming COVID Herd Immunity?

Many factors contribute to community-building COVID herd immunity. Are we close to having herd immunity against Covid-19? Can we achieve that? Let’s find the answer.

November 29, 2021
·
8 min read
·
Mishayl Hanan
First Day in a New Pharmacy Job: What to Expect

Starting your new pharmacy job can be scary, especially if you have never worked in a pharmacy before. Here is what to expect on your first day.

November 29, 2021
·
6 min read
·
Alina Zahid
Drug Development

Talaris is Rapidly Expanding as it Speeds Toward a First BLA

As the late-stage trials continue to progress, Talaris is rapidly ramping up its resources and investments.

November 29, 2021
·
7 min read
·
Heather McKenzie
Drug Development

Early-Stage Diabetes Treatment Wows Patients and Clinicians Alike

In October, Vertex Pharmaceuticals announced stunning results in a type 1 diabetes patient who had been dosed with the company’s experimental therapy.

November 29, 2021
·
3 min read
·
Alex Keown
Drug Development

VYJUVEK: Gene-Based Therapy for Rare Skin Disease Succeeds in Phase III

Results from its GEM-3 trial on VYJUVEK demonstrated statistical significance in its ability to promote complete wound healing within six months compared to a placebo.

November 29, 2021
·
2 min read
·
Vanessa Doctor, RN
Genetown

Boston Neighbors Net $256 Million for Treg and Allosteric Therapies

Quell Therapeutics scooped up $156 million in a Series B round this week. The company utilizes regulatory T cells to treat a variety of autoimmune and inflammatory diseases.

November 29, 2021
·
3 min read
·
Kate Goodwin
Business

Blueprint Adds Lengo’s Precision Therapy to Lung Cancer Portfolio

The deal adds LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations, to its pipeline.

November 29, 2021
·
3 min read
·
Alex Keown
Business

Turnstone and Moffitt Cancer Center Team Up on TILs

New York-based Turnstone Biologics announced it is partnering with the Moffitt Cancer Center to develop tumor-infiltrating lymphocyte (TIL) therapies.

November 29, 2021
·
2 min read
·
Mark Terry
Policy

Omicron Variant has Vaccine Makers Moving Fast and More COVID News

Omicron has caused the U.S. to install travel bans against several South African countries while vaccine makers rush to test their vaccines against it. For that news and more, continue reading.

November 29, 2021
·
5 min read
·
Mark Terry